keyword
MENU ▼
Read by QxMD icon Read
search

in NSCLC metastatic

keyword
https://www.readbyqxmd.com/read/29775109/outcomes-of-surgery-as-part-of-the-management-of-metastatic-non-small-cell-lung-cancer-a-surveillance-epidemiology-and-end-results-database-analysis
#1
Omar Abdel-Rahman
The role of local treatment in patients with oligometastatic non-small-cell lung cancer (NSCLC) is a subject of ongoing debate. This study assessed the survival impact of combined surgery to the primary tumor and metastatic disease in the management of metastatic NSCLC. Stage IV NSCLC patients at presentation, diagnosed from 2004 to 2013 were identified from the SEER (Surveillance, Epidemiology, and End Results) database. Propensity-matched analysis was performed considering baseline characteristics (age, gender, race, histology, TN stage, and site of metastases)...
April 21, 2018: Cancer Investigation
https://www.readbyqxmd.com/read/29774128/systematic-review-and-meta-analysis-of-selected-toxicities-of-approved-alk-inhibitors-in-metastatic-non-small-cell-lung-cancer
#2
Rubens Barros Costa, Ricardo L B Costa, Sarah M Talamantes, Jason B Kaplan, Manali A Bhave, Alfred Rademaker, Corinne Miller, Benedito A Carneiro, Devalingam Mahalingam, Young Kwang Chae
Introduction: Anaplastic lymphoma kinase ( ALK ) inhibitors are the mainstay treatment for patients with non-small cell lung carcinoma (NSCLC) harboring a rearrangement of the ALK gene or the ROS1 oncogenes. With the recent publication of pivotal trials leading to the approval of these compounds in different indications, their toxicity profile warrants an update. Materials and Methods: A systematic literature search was performed in July 2017. Studies evaluating US FDA approved doses of one of the following ALK inhibitors: Crizotinib, Ceritinib, Alectinib or Brigatinib as monotherapy were included...
April 24, 2018: Oncotarget
https://www.readbyqxmd.com/read/29774061/immunotherapy-in-non-metastatic-non-small-cell-lung-cancer-can-the-benefits-of-stage-iv-therapy-be-translated-into-earlier-stages
#3
REVIEW
Griet Deslypere, Dorothée Gullentops, Els Wauters, Johan Vansteenkiste
Over the last decade, several steps forward in the treatment of patients with stage IV non-small cell lung cancer (NCSLC) were made. Examples are the use of pemetrexed, pemetrexed maintenance therapy, or bevacizumab for patients with nonsquamous NSCLC. A big leap forward was the use of tyrosine kinase inhibitors in patients selected on the basis of an activating oncogene, such as epidermal growth factor receptor ( EGFR ) activating mutations or anaplastic lymphoma kinase ( ALK ) translocations. However, all of these achievements could not be translated into survival benefits when studied in randomized controlled trials in patients with nonmetastatic NSCLC...
2018: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/29765975/relationship-of-snp-rs2645429-in-farnesyl-diphosphate-farnesyltransferase-1-gene-promoter-with-susceptibility-to-lung-cancer
#4
Mehdi Dehghani, Zahra Samani, Hassan Abidi, Leila Manzouri, Reza Mahmoudi, Saeed Hosseini Teshnizi, Mohsen Nikseresht
Background and Purpose: The mevalonate pathway is one of the major metabolic pathways that use acetyl-CoA to produce sterols and isoprenoids. These compounds can be effective in the growth and development of tumors. One of the enzymes involved in the mevalonate pathway is FDFT1. Different variants of this gene are involved in the risk of suffering various diseases. The present study examined the relationship between FDFT1 rs2645429 polymorphism and the risk of nonsmall cell lung cancer (NSCLC) in a population from southern Iran...
2018: International Journal of Genomics
https://www.readbyqxmd.com/read/29748017/antiangiogenic-therapy-for-patients-with-aggressive-or-refractory-advanced-non-small-cell-lung-cancer-in-the-second-line-setting
#5
REVIEW
Martin Reck, Marina Chiara Garassino, Martina Imbimbo, Frances A Shepherd, Mark A Socinski, Jin-Yuan Shih, Anne Tsao, Pablo Lee, Katherine B Winfree, Andreas Sashegyi, Rebecca Cheng, Rocio Varea, Benjamin Levy, Edward Garon
A majority of patients with advanced or metastatic non-small cell lung cancer (NSCLC) will experience disease progression after first-line therapy. Patients who have advanced NSCLC that is especially aggressive, which is defined as disease that rapidly progresses on first-line treatment or disease that is refractory to first-line treatment, have a critical unmet medical need. These patients have a poor prognosis in the second-line setting. Several studies have recently shown that treatment with an antiangiogenic therapy may benefit these patients...
June 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29748010/canadian-cancer-trials-group-cctg-ind211-a-randomized-trial-of-pelareorep-reolysin-in-patients-with-previously-treated-advanced-or-metastatic-non-small-cell-lung-cancer-receiving-standard-salvage-therapy
#6
Penelope A Bradbury, Donald G Morris, Garth Nicholas, Dongsheng Tu, Moustapha Tehfe, John R Goffin, Frances A Shepherd, Richard W Gregg, Jeffrey Rothenstein, Christoper Lee, Sara Kuruvilla, Bruce D Keith, Vamsee Torri, Normand Blais, Desiree Hao, Grzegorz J Korpanty, Glenwood Goss, Barbara L Melosky, Mihaela Mates, Natasha Leighl, Jean-Pierre Ayoub, Joana Sederias, Harriet Feilotter, Lesley Seymour, Scott A Laurie
OBJECTIVES: Pelareorep (reolysin), a Dearing strain of reovirus serotype 3, has demonstrated oncolytic activity as single agent and synergy with chemotherapy. We evaluated pelareorep, combined with standard second-line chemotherapy in patients with non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: This randomized phase II trial enrolled patients with advanced or metastatic NSCLC after first line chemotherapy. After a safety run-in, patients were randomized 1:1 to chemotherapy (pemetrexed [500 mg/m2, non-squamous], or docetaxel [75 mg/m2], day 1 every 21 days]) +/- pelareorep (4...
June 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29748008/predicting-outcomes-in-patients-with-advanced-non-small-cell-lung-cancer-enrolled-in-early-phase-immunotherapy-trials
#7
Hossein Maymani, Kenneth Hess, Roman Groisberg, David S Hong, Aung Naing, Sarina Piha-Paul, Filip Janku, Siqing Fu, Apostolia M Tsimberidou, Shubham Pant, Daniel Karp, Shuang Liu, Ming Sun, John Heymach, George Simon, Funda Meric-Bernstam, Vivek Subbiah
OBJECTIVES: Immunotherapy (IO) has altered the non-small cell lung cancer (NSCLC) therapeutic landscape. However, the majority of patients do not respond to immune-checkpoint blockade, and subsequently either receive further chemotherapy or are referred for clinical trials. Here we examined the outcomes and predictors of response to IO in early phase clinical trials. MATERIALS AND METHODS: We analyzed the records of 74 patients with metastatic NSCLC that were enrolled on phase 1 IO trials within MD Anderson Cancer Center from 1/2010 to 7/2017...
June 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29740674/deacetylmycoepoxydiene-is-an-agonist-of-rac1-and-simultaneously-induces-autophagy-and-apoptosis
#8
Wei Xie, Wei Zhang, Mingwei Sun, Chunhua Lu, Yuemao Shen
Lung cancer is the second most common cause of cancer-related death in the world. Most cases of lung cancer are not curable, especially non-small cell lung cancer (NSCLC). Thus, novel treatment targets for this malignant disease are urgently needed. Here, we demonstrate the feasibility of Rac1 in treating p53-null human NSCLC H1299 as a novel drug target. Deacetylmycoepoxydiene (DA-MED), a cytotoxic natural polyketide, functions as a Rac1 agonist in p53-null NSCLC H1299 cells. DA-MED treatment drives Rac1 activation and promotes robust production of reactive oxygen species, activating mitochondrial permeability transition and the intrinsic apoptotic pathway...
May 9, 2018: Applied Microbiology and Biotechnology
https://www.readbyqxmd.com/read/29737033/clonally-related-primary-alk-rearranged-adenocarcinoma-and-associated-metastatic-lesions
#9
You-Cai Zhu, Yun-Te Deng, Wen-Xian Wang, Chun-Wei Xu, Wu Zhuang, Kai-Qi Du
ALK rearrangement is a driver gene in non-small cell lung cancer (NSCLC). ALK-positive tumors are sensitive to ALK-tyrosine kinase inhibitors (TKIs). The detection of key driver genes is crucial to enable personalized treatment. Different histomorphological patterns have different driver genes. Herein, we report the case of a 42-year-old male patient diagnosed with adenocarcinoma with different histomorphologies in the primary lung site (mucinous type) and lymph node metastasis (solid type), of the same genotype, both presenting with ALK rearrangement but negative for EGFR mutation...
May 8, 2018: Thoracic Cancer
https://www.readbyqxmd.com/read/29736155/noninferiority-of-99m-tc-ethylenedicysteine-glucosamine-as-an-alternative-analogue-to-18-f-fluorodeoxyglucose-in-the-detection-and-staging-of-non-small-cell-lung-cancer
#10
Dong Dai, F David Rollo, Jerry Bryant, E Edmund Kim
Objective. 99m Tc-ethylenedicysteine-glucosamine (99m Tc-EC-G) was developed as a potential alternative to 18 F-FDG for cancer imaging. A Phase 2 study was conducted to compare 18 F-FDG PET/CT and 99m Tc-EC-G SPECT/CT in the detection and staging of patients with non-small cell lung cancer (NSCLC). This study was aimed to demonstrate that 99m Tc-EC-G SPECT/CT was not inferior to 18 F-FDG PET/CT in patients with confirmed NSCLC. Methods. Seventeen patients with biopsy proven NSCLC were imaged with 99m Tc-EC-G and 18 F-FDG to detect and stage their cancers...
2018: Contrast Media & Molecular Imaging
https://www.readbyqxmd.com/read/29731873/mir-224-enhances-invasion-and-metastasis-by-targeting-hoxd10-in-non-small-cell-lung-cancer-cells
#11
Shuang Li, Jingang Zhang, Yunwei Zhao, Fengling Wang, Ying Chen, Xiubin Fei
Increasing number of studies have indicated aberrant microRNA (miRNA) expression could affect normal biological progress in non-small cell lung cancer (NSCLC) cells. This study was performed to evaluate the biologic functions of microRNA-224 (miR-224) in NSCLC. Real-time PCR was performed to evaluate the expression of miR-224 and Homeobox D10 (HOXD10) in NSCLC cell lines and tissues. Transwell assays were performed to investigate the function of miR-224 on NSCLC cell migration and invasion. Moreover, western blotting and luciferase assays were used to investigate HOXD10 as miR-224 downstream targets...
May 2018: Oncology Letters
https://www.readbyqxmd.com/read/29731854/cantharidin-suppresses-cell-growth-and-migration-and-activates-autophagy-in-human-non-small-cell-lung-cancer-cells
#12
Yan-Peng Liu, Ling Li, Liang Xu, E-Nuo Dai, Wei-Da Chen
Cantharidin (CTD), a component of Mylabris (blister beetle), is a traditional Chinese medicine that exerts an anticancer effect in multiple types of cancer cells. The aim of the present study was to investigate whether CTD exhibited anti-metastatic and inhibitory cell proliferation effects against human non-small cell lung cancer (NSCLC) A549 cells, and the possible underlying mechanism by which this occurs. The results of the present study demonstrated that CTD arrested proliferation, suppressed invasion and migration and induced apoptosis in A549 cells in vitro ...
May 2018: Oncology Letters
https://www.readbyqxmd.com/read/29729495/braf-in-non-small-cell-lung-cancer-nsclc-pickaxing-another-brick-in-the-wall
#13
REVIEW
Alessandro Leonetti, Francesco Facchinetti, Giulio Rossi, Roberta Minari, Antonia Conti, Luc Friboulet, Marcello Tiseo, David Planchard
Molecular characterization of non-small cell lung cancer (NSCLC) marked an historical turning point for the treatment of lung tumors harboring kinase alterations suitable for specific targeted drugs inhibition, translating into major clinical improvements. Besides EGFR, ALK and ROS1, BRAF represents a novel therapeutic target for the treatment of advanced NSCLC. BRAF mutations, found in 1.5-3.5% of NSCLC, are responsible of the constitutive activation of mitogen activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway...
April 24, 2018: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29726094/role-of-long-non-coding-rna-in-drug-resistance-in-non-small-cell-lung-cancer
#14
REVIEW
Leirong Wang, Leina Ma, Fei Xu, Wenxin Zhai, Shenghua Dong, Ling Yin, Jia Liu, Zhuang Yu
Lung cancer is the leading cause of cancer-associated death, and non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancer cases. Many drugs have been used to treat NSCLC in order to improve patient prognosis. Platinum-based chemotherapy is the first-line treatment for locally advanced or metastatic patients. For patients with activating EGFR mutations, tyrosine kinase inhibitors are the best treatment choice. NSCLC initially exhibits an excellent response to treatment; however, acquired resistance has been observed in many patients, leading to ineffective treatment...
May 3, 2018: Thoracic Cancer
https://www.readbyqxmd.com/read/29724633/iodine-125-seed-brachytherapy-inhibits-non-small-cell-lung-cancer-by-suppressing-epithelial-mesenchymal-transition
#15
Yana He, Liang Li, Jihua Liu, Xuening Zhang
PURPOSE: Metastatic non-small cell lung cancer (NSCLC) has posed a great clinical challenge with high mortality. Iodine-125 (I-125) seed brachytherapy has not been widely applied in clinic against NSCLC. METHODS AND MATERIALS: Mice were injected with human H23 NSCLC cells to establish a mouse xenograft model, which received I-125 seed implantation. The curative effect, pathological impairments, and survival rate of mice were investigated. Changes in the expression levels of epithelial-mesenchymal transition (EMT) markers, including N-cadherin, E-cadherin, and vimentin, in the xenograft tumors were analyzed using reverse transcription polymerase chain reaction and Western blot...
April 30, 2018: Brachytherapy
https://www.readbyqxmd.com/read/29716923/interferon-gamma-messenger-rna-signature-in-tumor-biopsies-predicts-outcomes-in-patients-with-non-small-cell-lung-carcinoma-or-urothelial-cancer-treated-with-durvalumab
#16
Brandon W Higgs, Christopher Morehouse, Katie L Streicher, Philip Brohawn, Fernanda Pilataxi, Ashok Gupta, Koustubh Ranade
PURPOSE: To identify a predictive biomarker for durvalumab, an anti-programmed death ligand 1 (PD-L1) monoclonal antibody. EXPERIMENTAL DESIGN: RNA sequencing of 97 advanced-stage non-small-cell lung carcinoma (NSCLC) biopsies from a nonrandomized phase 1b/2 clinical trial (1108/NCT01693562) were profiled to identify a predictive signature; 62 locally advanced or metastatic urothelial cancer (UC) tumors from the same study were profiled to confirm predictive utility of the signature...
May 1, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29707414/treatment-patterns-clinical-and-economic-outcomes-of-patients-with-anaplastic-lymphoma-kinase-positive-non-small-cell-lung-cancer-receiving-ceritinib-a-retrospective-observational-claims-analysis
#17
Anand A Dalal, Annie Guerin, Alex Mutebi, Kenneth W Culver
Objective: To describe patient characteristics, treatment patterns, healthcare resource utilization (HRU), and costs among patients with anaplastic lymphoma kinase ( ALK )-positive non-small cell lung cancer (NSCLC) receiving ceritinib in second or later line of therapy. Methods: Adult patients with NSCLC receiving ceritinib were identified from two large US claims databases (2006-2015). Patient characteristics, comorbidity profile, treatment patterns prior to ceritinib, and ceritinib dosing patterns were described...
2018: Journal of Drug Assessment
https://www.readbyqxmd.com/read/29707323/long-term-survival-without-surgery-in-nsclc-patients-with-synchronous-brain-oligometastasis-systemic-chemotherapy-revisited
#18
Jun Sato, Hidehito Horinouchi, Yasushi Goto, Shintaro Kanda, Yutaka Fujiwara, Hiroshi Nokihara, Noboru Yamamoto, Yuichiro Ohe
Background: Among patients with metastatic non-small-cell lung cancer (NSCLC), patients with TNM stage N0 to N1 and brain oligometastases (BOM) (less than 5 metastases) as the sole distant lesion (N0-1 BOM) who receive surgical treatments for the primary and metastatic sites reportedly have a better prognosis. Little data is available regarding the outcomes of patients treated with only systemic chemotherapy for the primary site and definitive treatment for synchronous BOM, compared with the outcomes of patients receiving surgical treatment for the primary site...
March 2018: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29707129/circulating-programmed-death-ligand-1-cpd-l1-in-non-small-cell-lung-cancer-nsclc
#19
Silvia Vecchiarelli, Francesco Passiglia, Armida D'Incecco, Marianna Gallo, Antonella De Luca, Elisa Rossi, Federica D'Incà, Gabriele Minuti, Lorenza Landi, Chiara Bennati, Michela Spreafico, Manolo D'Arcangelo, Valentina Mazza, Nicola Normanno, Federico Cappuzzo
Background: This study aimed at investigating feasibility of programmed death ligand-1 (PD-L1) testing in plasma samples of advanced NSCLC patients receiving first-line treatment, assessing whether circulating (c)PD-L1 levels were modified by the therapy and whether baseline cPD-L1 levels were associated with patients' clinical responses and survival outcome. Methods: Peripheral blood samples were collected from 16 healthy volunteers and 56 newly diagnosed NSCLC patients before and at 12th week during the course of first-line therapy...
April 3, 2018: Oncotarget
https://www.readbyqxmd.com/read/29704108/can-early-palliative-care-with-anticancer-treatment-improve-overall-survival-and-patient-related-outcomes-in-advanced-lung-cancer-patients-a-review-of-the-literature
#20
REVIEW
Massimo Ambroggi, Claudia Biasini, Ilaria Toscani, Elena Orlandi, Raffaella Berte, Martina Mazzari, Luigi Cavanna
PURPOSE: Metastatic non-small-cell lung cancer (NSCLC), the leading cause of death from cancer worldwide, is a debilitating disease that results in a high burden of symptoms and poor quality of life; the estimated prognosis after the diagnosis has been established was less than 1 year until some years ago. At the present, the new targeted therapies and immunotherapy are changing the course of the disease. However, advanced NSCLC remains an incurable disease, with a poor prognosis for the majority of the affected patients, so that quality of life and relief from symptoms are primary objectives of treatment...
April 27, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
keyword
keyword
116740
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"